Director/PDMR Shareholding

RNS Number : 0593W

Renalytix PLC

17 December 2021

 

Renalytix plc

("Renalytix" or the "Company")  

Director/PDMR Dealing

New York, 17 December 2021 - Renalytix (LSE: RENX) announces that it has been advised of the purchase by Ann Berman, the Company's Non-Executive Director, of 3,000 American Depositary Shares ("ADS") in open market purchases using personal funds, each representing two ordinary shares of £0.0025 each in the capital of the Company ("Ordinary Shares"), at an aggregate price of $14.00 per ADS.

Following completion of the purchase, Ann Berman is interested in 12,000 Ordinary Shares representing 0.02% of the current issued share capital of the Company.

For further information, please contact:  

Renalytix plc		www.renalytix.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)		Tel: [phone]
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)		Tel: [phone]
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: [phone]  or  [e-mail]
Paul McManus / Lianne Applegarth		Mob: [phone]

About KidneyIntelX

KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit  www.kidneyintelx.com ). For more information, visit  www.renalytix.com .

The information contained in this notification is disclosed in accordance with the requirements of MAR.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Ann Berman
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Renalytix plc
b)	Legal Entity Identifier	213800NTOH3FK3WER551
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	ADS', each ADS representing two Ordinary Shares of £0.0025 each. US75973T1016
b)	Nature of the transaction	Purchase of ADS'
c)	Currency	US Dollar
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		$14.00	3,000 ADS (representing 6000 Ordinary Shares)
e)	Aggregated information - Aggregated volume - Price - Aggregated total	3,000 ADS (representing 6,000 Ordinary Shares) $14.00 $42,000
f)	Date of the transaction	16 December 2021
g)	Place of the transaction	Nasdaq Stock Exchange

 

END

 

 

DSHEAFAXFAFFFFA